Severe COVID-19 and inactivated vaccine in diabetic patients with SARS-CoV-2 infection

Severe COVID-19 and inactivated vaccine in diabetic patients with SARS-CoV-2 infection

Saved in:

Bibliographic Details
Main Authors:	Yaling Yang, Feng Wei, Duoduo Qu, Xinyue Xu, Chenwei Wu, Lihua Zhou, Jia Liu, Qin Zhu, Chunhong Wang, Weili Yan, Xiaolong Zhao, Jinjiao Li
Format:	Article
Language:	English
Published:	Wolters Kluwer 2025-05-01
Series:	Chinese Medical Journal
Online Access:	http://journals.lww.com/10.1097/CM9.0000000000003577
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Age and primary vaccination schedule impact humoral and cellular immunity with an inactivated SARS-CoV-2 vaccine
by: Yohana Martínez-Balboa, et al.
Published: (2025-08-01)

Boosting with heterologous vaccines effectively improves protective immune responses of the inactivated SARS-CoV-2 vaccine
by: Jialu Zhang, et al.
Published: (2021-01-01)

Antibody response elicited by a third boost dose of inactivated SARS-CoV-2 vaccine can neutralize SARS-CoV-2 variants of concern
by: Lei Yue, et al.
Published: (2021-01-01)

Ethacridine inhibits SARS-CoV-2 by inactivating viral particles.
by: Xiaoquan Li, et al.
Published: (2021-09-01)

Naive and Memory B Cell BCR Repertoires in Individuals Immunized with an Inactivated SARS-CoV-2 Vaccine
by: Renato Kaylan Alves de Oliveira França, et al.
Published: (2025-04-01)

Development and in vivo evaluation of a SARS-CoV-2 inactivated vaccine using high hydrostatic pressure
by: Martina Brandolini, et al.
Published: (2025-04-01)

Rapid inactivation of SARS-CoV-2 with deep-UV LED irradiation
by: Hiroko Inagaki, et al.
Published: (2020-01-01)

Dynamic SARS-CoV-2-specific B-cell and T-cell responses induced in people living with HIV after a full course of inactivated SARS-CoV-2 vaccine
by: Xiuwen Wang, et al.
Published: (2025-02-01)

Low Antibody-Dependent Enhancement of Viral Entry Activity Supports the Safety of Inactivated SARS-CoV-2 Vaccines
by: Xiaofang Peng, et al.
Published: (2025-04-01)

Efficacy of Inactivated Bivalent SARS-CoV-2 Vaccines Targeting Ancestral Strain (ERAGEM), Delta, and Omicron Variants
by: Busra Kaplan, et al.
Published: (2025-02-01)

Inactivated SARS–CoV–2 Vaccine Inducing Acute Transverse Myelitis and Hypercoagulable State: A Case Report
by: Lisda Amalia
Published: (2025-02-01)

Cross-neutralization effect of the third dose of inactivated COVID-19 vaccine against the SARS-CoV-2 variants
by: Yuqing Li, et al.
Published: (2025-12-01)

Inactivated rabies virus vectored SARS-CoV-2 vaccine prevents disease in a Syrian hamster model.
by: Drishya Kurup, et al.
Published: (2021-03-01)

Vaccination with inactivated SARS-CoV-2 vaccine TURKOVAC induces durable humoral and cellular immune responses up to 8 months
by: Seçil Yılmaz, et al.
Published: (2025-04-01)

Viral Inactivation with Emphasis on SARS-CoV-2 Using Physical and Chemical Disinfectants
by: Abdolmajid Fadaei
Published: (2021-01-01)

Tergitol-15-S-9 inactivates SARS-CoV-2 and boosts immunoassay signals
by: Michael G Berg, et al.
Published: (2021-07-01)

Resilient SARS-CoV-2 diagnostics workflows including viral heat inactivation.
by: Maria Jose Lista, et al.
Published: (2021-01-01)

Hypocalcemia is associated with adverse outcomes in patients with diabetes and COVID-19
by: Xinyue Xu, et al.
Published: (2025-06-01)

Immune response to and virological profile of SARS-CoV-2 before and after symptom onset in individuals vaccinated with inactivated COVID-19 vaccines
by: Yandong Cheng, et al.
Published: (2025-12-01)

Transient severe myocarditis and intraventricular thrombus associated with SARS-CoV-2 vaccination
by: Alexander Loch, et al.
Published: (2023-06-01)

Safety and immunogenicity of inactivated SARS-CoV-2 vaccines in healthy individuals: protocol for a systematic review and meta-analysis
by: Mao Li, et al.
Published: (2021-11-01)

Prolonged Omicron-specific B cell maturation alleviates immune imprinting induced by SARS-CoV-2 inactivated vaccine
by: Ayijiang Yisimayi, et al.
Published: (2024-12-01)

Evaluation and Its Impact of SARS-CoV-2 Inactivated Vaccine Candidate in K18-hACE2 Mice
by: Rofiqul A'la, et al.
Published: (2025-04-01)

Racing for a SARS‐CoV‐2 vaccine
by: Özlem Türeci, et al.
Published: (2021-09-01)

A validated protocol to UV-inactivate SARS-CoV-2 and herpesvirus-infected cells.
by: Timothy K Soh, et al.
Published: (2023-01-01)

Inactivation of SARS-CoV-2 at acidic pH is driven by partial unfolding of spike
by: Irina Glas, et al.
Published: (2025-07-01)

Fast inactivation of SARS-CoV-2 by UV-C and ozone exposure on different materials
by: Elena Criscuolo, et al.
Published: (2021-01-01)

The impact of previous SARS-CoV-2 infection on post-vaccine adverse events in individuals vaccinated with TURKOVAC or CoronaVac –inactivated COVID-19 vaccines
by: Mine Durusu Tanriover, et al.
Published: (2024-12-01)

Biochemical and antigenic characterization of the structural proteins and their post-translational modifications in purified SARS-CoV-2 virions of an inactivated vaccine candidate
by: Xiao-Yu Zhang, et al.
Published: (2020-01-01)

Serum Fibronectin Levels Increased Significantly Following the Administration of an Inactivated SARS-CoV-2 Vaccine: A Prospective Observational Study
by: Zhao B, et al.
Published: (2025-04-01)

SARS-CoV-2 Alchemy: Understanding the dynamics of age, vaccination, and geography in the evolution of SARS-CoV-2 in India.
by: Mansi Patel, et al.
Published: (2025-03-01)

Risk factors and effectiveness of vaccination for nosocomial SARS-CoV-2 acquisition throughout the SARS-CoV-2 pandemic
by: Nishi Dave, et al.
Published: (2025-08-01)

A human cell-based SARS-CoV-2 vaccine elicits potent neutralizing antibody responses and protects mice from SARS-CoV-2 challenge
by: Xiangchuan He, et al.
Published: (2021-01-01)

Evaluation and Clinical Validation of Guanidine-Based Inactivation Transport Medium for Preservation of SARS-CoV-2
by: Hesti L. Wiraswati, et al.
Published: (2022-01-01)

Equine Hyperimmune Serum against the Inactivated SARS-CoV-2 Has Antibodies Neutralizing Titers
by: Neida Lucia Conrad, et al.
Published: (2025-07-01)

The Effectiveness of Four Quadrivalent, Inactivated Influenza Vaccines Administered Alone or in Combination with Pneumococcal and/or SARS-CoV-2 Vaccines: A Population-Wide Cohort Study
by: Cecilia Acuti Martellucci, et al.
Published: (2025-03-01)

Vaccination against the SARS-CoV-2 in individuals with comorbidities
by: S A Berns, et al.
Published: (2025-02-01)

Timely development of vaccines against SARS-CoV-2
by: Shan Lu
Published: (2020-01-01)

Prevalence of Vaccination among Patients with SARS-CoV-2
by: Falah Hasan Obayes Al-Khikani
Published: (2024-07-01)

Pulmonary embolism after SARS-CoV-2 vaccination
by: Björn Zethelius, et al.
Published: (2024-12-01)